The adenosine A 2A receptor antagonist, istradefylline improves motor function in patients
with advanced Parkinson's disease (PD) optimally treated with a combination of l-DOPA and …

The 8-substituted 9-ethyladenine derivatives: 8-bromo-9-ethyladenine (ANR 82), 8-ethoxy-9-
ethyladenine (ANR 94), and 8-furyl-9-ethyladenine (ANR 152) have been characterized in …

In high throughput screening of our file compounds, a novel structure 1 was identified as a
potent A2A receptor antagonist with no selectivity over the A1 adenosine receptor. The …

Abstract KW‐6002, a xanthine‐based adenosine A2A antagonist, was labelled with the
positron emitter carbon‐11 by O‐methylation of its precursor, KF23325, using [11C] …

There is now growing interest in the functional role of adenosine A2A receptors. Their
distribution within the brain is restricted in the basal ganglia, particularly abundant in the …

Introduction: Despite several available therapeutic options to treat the symptoms of
Parkinson's disease (PD), there are currently no agents that halt or slow the progression of …

Parkinson's disease is the second most common neuro degenerative disorder and affects
over 1 million people in North America. The pathological process, degeneration of the …

Caffeine has been shown to increase brain and plasma content of neurosteroid 3α-hydroxy-
5α-pregnan-20-one (3α, 5α-THP) that allosterically modulates GABAA receptors. The …

Adenosine receptors modulate dopaminergic function by regulating dopamine release in
presynaptic neurons and intracellular signaling in postsynaptic striatal neurons. To …

Methylenedioxymethamphetamine (MDMA,“ecstasy”) popular as a designer drug is often
used with caffeine to gain a stronger stimulant effect. MDMA induces 5-HT and DA release …